Antitrust
Delaware Court Denies Pfizer’s Bid to Block Novo Nordisk-Metsera Deal
Delaware Court; Pfizer; Novo Nordisk; Metsera; temporary restraining order; merger agreement; antitrust; FTC; obesity drugs
Metsera Bidding War Grips Obesity Drug Field as Novo Nordisk and Pfizer Escalate Offers
Metsera; obesity drugs; bidding war; Novo Nordisk; Pfizer; acquisition; GLP-1; antitrust; market dominance; legal disputes
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama
Novo Nordisk; Metsera; acquisition; Pfizer; buyout; obesity drugs; analysts; lawsuit; antitrust; CEO Mike Doustdar
Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law
Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs
Sandoz Reaches $275 Million Settlement in US Generic Drug Price Fixing Case
Sandoz, generic drug price fixing, settlement, antitrust litigation, pharmaceutical industry
EU High Court Rules in Favor of Illumina in Grail Acquisition Appeal
Illumina, Grail, European Court of Justice, Acquisition, Antitrust Litigation, Liquid Biopsy
Ex-Pharmaceutical Executive Receives Probation in Antitrust Violation Case
Pharmaceutical industry, antitrust violation, price-fixing, Sandoz, executive, sentencing, probation
European Commission Grants Approval for Illumina to Divest Grail
Illumina, Grail, European Commission, Divestment, Competition, Antitrust
Regeneron Antitrust Suit Against Novartis Gains Momentum with Appellate Ruling
Regeneron, Novartis, Antitrust lawsuit, Appeal court backing, Eye treatments (Eylea & Lucentis), Patent dispute